Please assess the completion status of the following clinical trial:

Trial Title: The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged between 7 and 15 years~* Patients who have received a diagnosis of perennial allergic rhinitis according to the diagnostic criteria~* Patients with a mean rhinorrhea score and a mean sneezing score of at least 2 on the basis of symptoms recorded in the nasal allergy diary during the observation period etc.~Exclusion Criteria:~* Patients with vasomotor rhinitis or eosinophilic rhinitis~* Patients who have concurrent nasal disease that may affect the efficacy of TAU-284~* Patients with a history of any of the nasal surgical procedures~* Patients who have a positive result for pollen antigens which are dispersed during the study period~* Patients who have a positive result for dog dander or cat dander antigen and have a chance to touch dogs or cats.~* Patients with current or previous history of drug allergy~* Patients who concurrently have renal function abnormalities that may cause safety problems etc.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- TAU-284 (Type: EXPERIMENTAL): Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).

Based on this trial design, predict the completion outcome and termination type (if applicable).